Analysts’ Top Healthcare Picks: Thermo Fisher (TMO), Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Thermo Fisher (TMO) and Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR) with bullish sentiments.

Meet Samuel – Your Personal Investing Prophet

• Start a conversation with TipRanks’ trusted, data-backed investment intelligence
• Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Thermo Fisher (TMO)

TD Cowen analyst Daniel Brennan maintained a Buy rating on Thermo Fisher on May 20. The company’s shares closed last Thursday at $449.37.

According to TipRanks.com, Brennan is a 5-star analyst with an average return of 14.1% and a 47.2% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Thermo Fisher is a Strong Buy with an average price target of $608.93, implying a 35.0% upside from current levels. In a report issued on May 8, Wells Fargo also maintained a Buy rating on the stock with a $615.00 price target.

See the top stocks recommended by analysts >>

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR)

In a report issued on May 15, Dennis Hulme from Taylor Collison maintained a Buy rating on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh, with a price target of A$3.45. The company’s shares closed last Friday at A$1.82.

Hulme has an average return of 2.0% when recommending Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh. ;'>

According to TipRanks.com, Hulme is ranked #10013 out of 12258 analysts.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an analyst consensus of Strong Buy, with a price target consensus of A$2.92, representing a 59.6% upside. In a report issued on May 19, Canaccord Genuity also assigned a Buy rating to the stock with a A$2.28 price target.

Read More on TMO:

Disclaimer & DisclosureReport an Issue

• Thermo Fisher Scientific: Buy Rating Reaffirmed on Strengthening Organic Growth Outlook, Market Share Gains, and AI-Driven Demand Tailwinds
• Thermo Fisher highlights growth outlook, long-term value creation
• Thermo Fisher sees low-teens adjusted EPS growth over the long-term
• Amazon among seven added to Jefferies’ Franchise Picks list
• Thermo Fisher resumed with a Sector Perform at RBC Capital